SEC 13F Intelligence

Managers / Q3 2019 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$279M
Q3 2019
Positions
49
Filings on Record
24
2019–present window
Filed
Nov 25, 2019
amendment (RESTATEMENT)

Summary

Endurant Capital Management LP reported $279M in U.S.-listed holdings across 49 positions for Q3 2019.

Its largest position, RCMEUR, represents 7.6% of the portfolio.

Compared with Q2 2019, the fund opened 18 new positions and exited 19.

Portfolio Metrics

Turnover
+47.8%
vs prior filed quarter
Top-10 Concentration
+56.0%
share of reported value
Largest Position
+7.6%
R1 Rcm
New / Exited
18 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 71.8%Other: 14.9%ETP: 7.1%US DOMESTIC: 3.4%ADR: 2.9%
  • Common Stock · 71.8% · $200M
  • Other · 14.9% · $41M
  • ETP · 7.1% · $20M
  • US DOMESTIC · 3.4% · $9M
  • ADR · 2.9% · $8M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR S&P 500 ETF TRNEW+66.2K66.2K+$20M$20M
JNJJOHNSON & JOHNSONNEW+107.4K107.4K+$14M$14M
CHARLES RIV LABS INTL INCNEW+75.0K75.0K+$10M$10M
ZTSZOETIS INCNEW+61.0K61.0K+$8M$8M
ELVANTHEM INCNEW+25.7K25.7K+$6M$6M
BDXBECTON DICKINSON & CONEW+22.1K22.1K+$6M$6M
HAEHAEMONETICS CORPNEW+32.6K32.6K+$4M$4M
NUCANA PLCNEW+384.7K384.7K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RCMEURR1 RCM INChistory →COM7.62%$21M2.38M
2ZBHZIMMER BIOMET HLDGS INChistory →COM7.51%$21M152.5K
3HCAHCA HEALTHCARE INChistory →COM6.47%$18M149.8K
4OXFORD IMMUNOTEC GLOBAL PLCORD SHS5.91%$16M989.4K
5LABORATORY CORP AMER HLDGSCOM NEW5.37%$15M89.0K
6BMYBRISTOL MYERS SQUIBB COhistory →COM5.31%$15M291.9K
7JNJJOHNSON & JOHNSONhistory →COM4.99%$14M107.4K
8PRAHPRA HEALTH SCIENCES INChistory →COM4.52%$13M126.8K
9ABBVABBVIE INChistory →COM4.40%$12M162.0K
10CICIGNA CORP NEWhistory →COM3.93%$11M72.1K
11CHARLES RIV LABS INTL INCCOM3.56%$10M75.0K
12ABGAMERISOURCEBERGEN CORPhistory →COM3.12%$9M105.5K
13EVOLENT HEALTH INCNOTE 2.000%12/02.86%$8M91.0K
14ZTSZOETIS INChistory →CL A2.73%$8M61.0K
15WRIGHT MED GROUP N VORD SHS2.23%$6M301.4K
16ELVANTHEM INChistory →COM2.21%$6M25.7K
17BDXBECTON DICKINSON & COhistory →COM2.00%$6M22.1K
18IARTINTEGRA LIFESCIENCES HLDGS Chistory →COM NEW1.82%$5M84.2K
19HAEHAEMONETICS CORPhistory →COM1.48%$4M32.6K
20SIENUSDSIENTRA INChistory →COM1.23%$3M530.0K
21SNYSANOFIhistory →SPONSORED ADR1.12%$3M67.2K
22NUCANA PLCSPONSORED ADR1.00%$3M384.7K
23FATEFATE THERAPEUTICS INCCOM0.93%$3M166.8K
24BUWABIO RAD LABS INCCL A0.83%$2M6.9K
25GW PHARMACEUTICALS PLCADS0.71%$2M17.1K
26ACRSACLARIS THERAPEUTICS INCCOM0.69%$2M1.77M
27INSPINSPIRE MED SYS INCCOM0.67%$2M30.8K
28SDCCQSMILEDIRECTCLUB INCCL A COM0.66%$2M133.4K
29FLBFLUIDIGM CORP DELCOM0.66%$2M395.7K
30TAKEDA PHARMACEUTICAL CO LTDSPONSORED ADS0.57%$2M92.3K
31IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.56%$2M86.1K
32SENSEONICS HLDGS INCNOTE 5.250% 2/00.53%$1M1.50M
33IINUSDINTRICON CORPCOM0.51%$1M73.5K
34AZNNASTRAZENECA PLCSPONSORED ADR0.50%$1M31.0K
35CNMDCONMED CORPCOM0.45%$1M13.1K
36LQDALIQUIDIA TECHNOLOGIES INCCOM0.41%$1M318.0K
37HUMHUMANA INCCOM0.36%$997,0003.9K
38PETQEURPETIQ INCCOM CL A0.34%$936,00034.4K
39ATRCATRICURE INCCOM0.31%$858,00034.4K
40EHCENCOMPASS HEALTH CORPCOM0.27%$753,00011.9K
41AXNX*AXONICS MODULATION TECH INCCOM0.27%$747,00027.8K
42ACHCACADIA HEALTHCARE COMPANY INCOM0.27%$743,00023.9K
43PROTHENA CORP PLCSHS0.24%$677,00086.4K
44XENTEURINTERSECT ENT INCCOM0.23%$643,00037.8K
45GNCAQGENOCEA BIOSCIENCES INCCOM NEW0.20%$546,000188.1K
46APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.19%$537,00022.3K
47NEON THERAPEUTICS INCCOM0.12%$332,000193.1K
48ATNMEURACTINIUM PHARMACEUTICALS INCCOM0.11%$311,0001.35M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.